U.S., July 29 -- ClinicalTrials.gov registry received information related to the study (NCT07088471) titled 'Cardiac Left Atrial Evaluation and Response in HFrEF With Sacubitril/Valsartan' on July 20.
Brief Summary: Heart failure is an increasingly common condition which can have a significant impact on quality of life and reduce life expectancy. In recent decades, a number of drugs have been developed specifically for this condition. One such drug, called Sacubitril/valsartan (SV) has been shown to reduce hospitalizations and prolong life expectancy of patients with heart failure. It works by reversing some of the structural and functional changes to the heart which occur in heart failure. However, not all patients respond to the drug. Fu...